Core Viewpoint - The company announced advancements in its technology, particularly in the area of targeted conjugates, which have been clinically validated to significantly reduce blood toxicity in ADCs [2] Group 1: Technology Advancements - The company's targeted conjugate technology has been clinically validated, demonstrating a change in the toxicity profile of ADCs and significantly reducing blood toxicity [2] - Clinical development of products will require a balanced consideration of target and indication needs [2] Group 2: Intellectual Property - The LNP mRNA company possesses independent intellectual property rights [2]